MYC and cancer: In addition to degrading total and chromatin-bound WDR5 (Fig. 5D), MS67 also decreased chromatin-bound fractions of MLL complex components, such as MLL, RBBP5, and Menin, and c-MYC (Fig. 5D), another WDR5 partner in cancer (17, 41).